Showing posts with label colon cancer research journals. Show all posts
Showing posts with label colon cancer research journals. Show all posts

Thursday, 25 May 2017

Functional Assessment of Quality of Life Using EORTC QLQ-CR29 in Patients with Colon Cancer at King Abdulaziz University Hospital

Colorectal cancer is the third most common cancer in the world. Quality of life is important to achieve successful treatment outcomes.

The aim of this study was to assess the functional quality of life of patients with newly diagnosed colorectal cancer in order to improve our understanding as physicians of how cancer therapy influences the patients’ lives, and how we can help patients improve the quality of life on a daily basis.
Colon Cancer

This was a cross-sectional study conducted between January-September 2013, of a sample of 647 patients newly diagnosed with colon cancer at the King Abdulaziz University Hospital, Jeddah, Saudi Arabia.

Tuesday, 23 August 2016

Anti-VEGFR2 Driven Nuclear Translocation of VEGFR2

lioblastoma (GBM) is considered as hypervascular, hypoxic and most malignant form of glioma. GBM is most lethal during first year after initial diagnosis despite surgical resection, radiotherapy and/ or chemotherapy. Anti-Angiogenic Therapies (AAT) are being used as an adjuvant mainly against Vascular Endothelial Growth Factor and its receptors (VEGF-VEGFRs) in endothelial cells to normalize tumor vasculatures. Due to lower genetic instability in endothelial cells compared to in tumor cells, it was anticipated that targeting VEGFVEGFR pathways, primarily in endothelial cells, would decrease tumor vasculature without imposing drug resistance. However, treatments provided minimal to none effect with no change in overall patients survival.

Similar data was obtained from preclinical studies. For example, VEGFR2 blockade in GBM through vatalanib, a receptor tyrosine kinase inhibitor, increased tumor size through hypoxia mediated overexpression of VEGF, SDF-1α, HIF-1α, VEGFR2, VEGFR3 and EGFR at peripheral part of tumors compared to central part. Activation of alternative pathways of angiogenesis, vasculogenesis and involvement of stem cells were observed following AAT in GBM, which was associated with overexpression of bFGF, angiopoietin1/2, GCSF, and SDF1α. 

Conventionally, tumor vessel formation occurs through angiogenesis, which is mediated by proliferation and migration of resident ECs.However, at a cellular level, up-regulation of HIF- 1α and SDF-1α by tumor cells resulted into recruitment of CXCR4+ Bone Marrow Derived Cells (BMDCs) to the tumor. BMDCs play a pivotal role in tumor development. Endothelial Progenitor Cells (EPCs) from BM pool are recruited in Tumor Microenvironment and contributed to vasculogenesis.


Anti-VEGFR2 Driven Nuclear Translocation of VEGFR2

lioblastoma (GBM) is considered as hypervascular, hypoxic and most malignant form of glioma. GBM is most lethal during first year after initial diagnosis despite surgical resection, radiotherapy and/ or chemotherapy. Anti-Angiogenic Therapies (AAT) are being used as an adjuvant mainly against Vascular Endothelial Growth Factor and its receptors (VEGF-VEGFRs) in endothelial cells to normalize tumor vasculatures. Due to lower genetic instability in endothelial cells compared to in tumor cells, it was anticipated that targeting VEGFVEGFR pathways, primarily in endothelial cells, would decrease tumor vasculature without imposing drug resistance. However, treatments provided minimal to none effect with no change in overall patients survival.

Nuclear Translocation
Similar data was obtained from preclinical studies. For example, VEGFR2 blockade in GBM through vatalanib, a receptor tyrosine kinase inhibitor, increased tumor size through hypoxia mediated overexpression of VEGF, SDF-1α, HIF-1α, VEGFR2, VEGFR3 and EGFR at peripheral part of tumors compared to central part. Activation of alternative pathways of angiogenesis, vasculogenesis and involvement of stem cells were observed following AAT in GBM, which was associated with overexpression of bFGF, angiopoietin1/2, GCSF, and SDF1α. 

Conventionally, tumor vessel formation occurs through angiogenesis, which is mediated by proliferation and migration of resident ECs.However, at a cellular level, up-regulation of HIF- 1α and SDF-1α by tumor cells resulted into recruitment of CXCR4+ Bone Marrow Derived Cells (BMDCs) to the tumor. BMDCs play a pivotal role in tumor development. Endothelial Progenitor Cells (EPCs) from BM pool are recruited in Tumor Microenvironment and contributed to vasculogenesis.


Wednesday, 10 August 2016

Neuropeptides in the Development of Colon Cancer

The American neuro-gastroenterologist Gershon has precisely nicknamed the intestines as ‘The second brain’, taking into account the size and complexity of the enteric nervous system (ENS). Enterochromaffin cells (EC) are functionally connected with the ENS and can also synthesize neuropeptides to control intestinal functions. Novel evidence has shown that EC indeed differentiates from the intestinal cryptal stem cell niche. Besides, mammalian bombesinlike peptides, cholecystokinin (CCK), gastrin, and neurotensin are gastrointestinal neuropeptides that impact on the body development, inflammation, tissue regeneration, and neoplastic transformation.


These molecules signal through their receptors that are highly expressed in the human colon but have, however, a differentiated pattern of expression for each one of them, which might illustrate their specific physiological roles. Hence, GRP receptors, Y2 receptors, PACAP type1-receptors, cholecystokinin-A receptors, neurotensin1 and somatostatin st2 receptors were abundantly expressed in the myenteric plexus, whereas VIP/PACAP and sst2 receptors were found in lymphoid follicles, and Y2, VIP type1 and sst2 receptors were present in the colonic mucosa. Specific binding sites for VIP, have been characterized in isolated human colonic epithelial cells in the early 80s. Given that the intestinal neuro-immune axis plays a significant role in regulating the severity of inflammation, it possibly has a pivotal role in the colon cancer development. For instance, neuropeptides might have either anti-inflammatory (VIP and galanin) or pro-inflammatory effects (NPY, substance P, serotonin, and neurotensin). The activation of specific immune signaling pathways might be the key to understanding the complex and controversial effects of these neuropeptides, from which inflammatory signals increase in a cascade of events. Corticotropin-releasing factor (CRF), which is a stress peptide, has been shown to control the colonic IL-6 release and neuronal activation, a fact that helps to clarify the effects of stressful conditions on the development of colonic inflammation.


Whether colitis increases the expression of neuropeptide Y (NPY) in the enteric nervous system, NPY knockout mice showed reduced intestinal inflammation. Pharmacological inhibition of vasoactive intestinal peptide (VIP), which is a neurotransmitter and vasodilator, protected experimental models from colitis. VIP-deficient mice, authors have also found reduced inflammation in trinitrobenzene sulfonic acid-induced colitis. Then, glucagon-like peptide 2 (GLP-2), which is an enteroendocrine hormone trophic for intestinal mucosa, has been shown to increase enteric neuronal expression of VIP. Sigalet et al. suggested that GLP-2 acts on enteric neurons and glial cells via a PI3Kγ/Akt pathway, stimulating neuronal differentiation via mTOR and ERK pathways, as well as the expression of receptors and ligands for IGF-I and ErbB pathways. Conversely, the anti-inflammatory and blood flow effects of GLP-2 are related to VIP and nitric oxide synthesizes and release from submucosal enteric neurons.